mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for SFN
Gene summary
Basic gene Info.Gene symbolSFN
Gene namestratifin
SynonymsYWHAS
CytomapUCSC genome browser: 1p36.11
Type of geneprotein-coding
RefGenesNM_006142.3,
Description14-3-3 protein sigma14-3-3 sigmaepithelial cell marker protein 1
Modification date20141222
dbXrefs MIM : 601290
HGNC : HGNC
Ensembl : ENSG00000175793
HPRD : 03185
Vega : OTTHUMG00000004093
ProteinUniProt: P31947
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_SFN
BioGPS: 2810
PathwayNCI Pathway Interaction Database: SFN
KEGG: SFN
REACTOME: SFN
Pathway Commons: SFN
ContextiHOP: SFN
ligand binding site mutation search in PubMed: SFN
UCL Cancer Institute: SFN
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0001836release of cytochrome c from mitochondria11574543
GO:0008630intrinsic apoptotic signaling pathway in response to DNA damage11574543
GO:0043154negative regulation of cysteine-type endopeptidase activity involved in apoptotic process11574543


Top
Ligand binding site mutations for SFN

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
E31E31DBLCA1
G171L172QCOAD1
E110G112WGBM1
E133E133KHNSC1
D225D225NHNSC1
E80E80QLUAD1
K49K49NLUSC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for SFN
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
E133E133K-1.3129216
G171L172Q-0.93127614
K49K49N-0.92012161
D225D225N-0.75726986
E31E31D-0.74275051
E110G112W-0.66656763
E80E80Q-0.53173493
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for SFN from PDB

Top
Differential gene expression and gene-gene network for SFN
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of SFN and the right PPI network was created from samples without mutations in the LBS of SFN. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for SFN
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0007137Carcinoma, Squamous Cell8AlteredExpression, Biomarker
umls:C2239176Carcinoma, Hepatocellular4Biomarker
umls:C0279626Esophageal Squamous Cell Carcinoma3Biomarker
umls:C0026640Mouth Neoplasms2Biomarker, PostTranslationalModification
umls:C0152013Adenocarcinoma of lung2Biomarker
umls:C0014859Esophageal Neoplasms2Biomarker
umls:C0024232Lymphatic Metastasis2Biomarker
umls:C0022548Keloid1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for SFN
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of SFN go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
MGMAGNESIUM(2+)3iqvAE110
MGMAGNESIUM(2+)3p1nAE110
MGMAGNESIUM(2+)3p1qAE110
MGMAGNESIUM(2+)3smlAE110
MGMAGNESIUM(2+)3smmAE110
MGMAGNESIUM(2+)3smnAE110
MGMAGNESIUM(2+)3smoAE110
MGMAGNESIUM(2+)3sprAE110
MGMAGNESIUM(2+)3t0lAE110
MGMAGNESIUM(2+)3t0mAE110
MGMAGNESIUM(2+)3u9xAE110
MGMAGNESIUM(2+)3ux0AE110
MGMAGNESIUM(2+)4datAE110
MGMAGNESIUM(2+)4fr3AE110
MGMAGNESIUM(2+)4dhmAE110
MGMAGNESIUM(2+)4dhnAE110
MGMAGNESIUM(2+)4dhoAE110
MGMAGNESIUM(2+)4dhqAE110
MGMAGNESIUM(2+)4dhrAE110
MGMAGNESIUM(2+)4dhsAE110
MGMAGNESIUM(2+)4dhtAE110
MGMAGNESIUM(2+)4dhuAE110
MGMAGNESIUM(2+)4qliAE110
CACALCIUM(2+)1ywtBE31
MGMAGNESIUM(2+)3smkAE31
MGMAGNESIUM(2+)3p1oAE80
MGMAGNESIUM(2+)4dhpAE80
IIIPeptide ligand (GLN,ARG,SER,THR,SER,THR)3iqvAG171
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1nAG171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1oAG171 D225
CACALCIUM(2+)3p1qAK49
FJAFUSICOCCIN J AGLYCONE(1S,4R,5R,6R,6AS,9S,9AE,10AR)-9-(METHOXYMETHYL)-6,10A- DIMETHYL-3-(PROPAN-2-YL)-1,2,4,5,6,6A,7,8,9,10A- DECAHYDRODICYCLOPENTA[A,D][8]ANNULENE-1,4,5-TRIOL3smmAK49
IIIPeptide ligand (PHE,TYR,PRO,SER,ALA,GLU)4datAK49
FSCFUSICOCCIN4jddAK49
Y07[2-(2-{[2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}-2- OXOETHOXY)PHENYL]PHOSPHONIC ACID4dhpAK49
IIIPeptide ligand (THR,PRO,SER,LEU,PRO)4fl5BK49
IIIPeptide ligand (ARG,THR,PRO,SEP,LEU,PRO,THR)4y32AK49
IIIPeptide ligand (THR,PRO,SEP,LEU,PRO,THR)4y32BK49
IIIPeptide ligand (THR,PRO,SEP,LEU,PRO,THR)4y3bBK49
IIIPeptide ligand (ACE,ARG,THR,PRO,SER,LEU,PRO,THR,PIP)4y5iAK49
IIIPeptide ligand (THR,PRO,SER,LEU,PRO,THR)4y5iBK49
IIIPeptide ligand (MET,ALA,ARG,SER,HIS,SER,TYR,PRO,ALA)1ywtBK49 D225
IIIPeptide ligand (PHE,LYS,THR,GLU,GLY,PRO,ASP)3lw1AK49 D225
IIIPeptide ligand (SER,HIS,THR,LEU,PRO,CYS)4qliAK49 D225
IIIPeptide ligand (ARG,THR,PRO,SER,LEU,PRO,THR,PRO)4fl5AK49 E133 G171
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1pAK49 E133 G171 D225
IIIPeptide ligand (SER,HIS,SER,TYR,PRO,ALA)1ywtAK49 G171
IIIPeptide ligand (GLN,ARG,SER,THR,SER,THR,PRO,ASN)3iqjAK49 G171
IIIPeptide ligand (GLN,ARG,SER,THR,SER,THR)3iquAK49 G171
IIIPeptide ligand (ARG,SER,THR,SER,THR,PRO,ASN,VAL)3o8iAK49 G171
IIIPeptide ligand (ALA,MET,SER,PHE,GLN,SER)4dauAK49 G171
IIIPeptide ligand (PHE,PRO,ALA,THR,VAL)4jc3AK49 G171
IIIPeptide ligand (PHE,PRO,ALA,THR,VAL)4jddAK49 G171
IIIPeptide ligand (ARG,SER,ALA,SER,GLU,PRO,SER,LEU)4ieaAK49 G171
IIIPeptide ligand (ARG,THR,PRO,SEP,LEU,PRO,THR)4y3bAK49 G171
IIIPeptide ligand (ARG,ALA,HIS,SER,SER,PRO,ALA,SER,LEU,GLN)3mhrAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1qAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1rAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3p1sAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3smkAK49 G171 D225
IIIPeptide ligand (ARG,ARG,LYS,SER,VAL)3smlAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3smmAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3smnAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3smoAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3sprAK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)3ux0AK49 G171 D225
IIIPeptide ligand (LYS,ARG,ARG,LYS,SER,VAL)4fr3AK49 G171 D225


Top
Conservation information for LBS of SFN
Multiple alignments for P31947 in multiple species
LBSAA sequence# speciesSpecies
A43Homo sapiens, Bos taurus, Mus musculus
A57VGGQRAAWRVL3Homo sapiens, Bos taurus, Mus musculus
D211HTLSEDSYKDS3Homo sapiens, Bos taurus, Mus musculus
D215EDSYKDSTLIM3Homo sapiens, Bos taurus, Mus musculus
D225MQLLRDNLTLW3Homo sapiens, Bos taurus, Mus musculus
E110SHLIKEAGDAE1Homo sapiens
E110THLIKEAGDAE1Bos taurus
E110SHLIKGAGDAE1Mus musculus
E133YRYLAEVATGD3Homo sapiens, Bos taurus, Mus musculus
E182SVFHYEIANSP3Homo sapiens, Bos taurus, Mus musculus
E23Homo sapiens, Bos taurus, Mus musculus
E31MKSAVEKGEEL2Bos taurus, Mus musculus
E31MKGAVEKGEEL1Homo sapiens
E35VEKGEELSCEE3Homo sapiens, Bos taurus, Mus musculus
E80EEKGPEVREYR1Homo sapiens
E80EEKGPEVQEYR1Bos taurus
E80EEKGPEVKEYR1Mus musculus
E83GPEVREYREKV1Homo sapiens
E83GPEVQEYREKV1Bos taurus
E83GPEVKEYREKV1Mus musculus
F119AESRVFYLKMK3Homo sapiens, Bos taurus, Mus musculus
G171NPIRLGLALNF3Homo sapiens, Bos taurus, Mus musculus
G53YKNVVGGQRAA3Homo sapiens, Bos taurus, Mus musculus
G78GSEEKGPEVRE1Homo sapiens
G78SSEEKGPEVQE1Bos taurus
G78GSEEKGPEVKE1Mus musculus
H106GLLDSHLIKEA1Homo sapiens
H106GLLDTHLIKEA1Bos taurus
H106GLLDSHLIKGA1Mus musculus
I168PPTNPIRLGLA3Homo sapiens, Bos taurus, Mus musculus
I183VFHYEIANSPE3Homo sapiens, Bos taurus, Mus musculus
I219KDSTLIMQLLR3Homo sapiens, Bos taurus, Mus musculus
K122RVFYLKMKGDY3Homo sapiens, Bos taurus, Mus musculus
K214SEDSYKDSTLI3Homo sapiens, Bos taurus, Mus musculus
K49LSVAYKNVVGG3Homo sapiens, Bos taurus, Mus musculus
K77EGSEEKGPEVR1Homo sapiens
K77ESSEEKGPEVQ1Bos taurus
K77EGSEEKGPEVK1Mus musculus
K87REYREKVETEL1Homo sapiens
K87QEYREKVETEL1Bos taurus
K87KEYREKVETEL1Mus musculus
L174RLGLALNFSVF3Homo sapiens, Bos taurus, Mus musculus
L218YKDSTLIMQLL3Homo sapiens, Bos taurus, Mus musculus
L222TLIMQLLRDNL3Homo sapiens, Bos taurus, Mus musculus
L229RDNLTLWTADN2Homo sapiens, Bos taurus
L229RDNLTLWTADS1Mus musculus
L43CEERNLLSVAY3Homo sapiens, Bos taurus, Mus musculus
M123VFYLKMKGDYY3Homo sapiens, Bos taurus, Mus musculus
N175LGLALNFSVFH3Homo sapiens, Bos taurus, Mus musculus
N226QLLRDNLTLWT3Homo sapiens, Bos taurus, Mus musculus
N42SCEERNLLSVA3Homo sapiens, Bos taurus, Mus musculus
N50SVAYKNVVGGQ3Homo sapiens, Bos taurus, Mus musculus
P167MPPTNPIRLGL3Homo sapiens, Bos taurus, Mus musculus
R129KGDYYRYLAEV3Homo sapiens, Bos taurus, Mus musculus
R56VVGGQRAAWRV3Homo sapiens, Bos taurus, Mus musculus
R60QRAAWRVLSSI3Homo sapiens, Bos taurus, Mus musculus
S45ERNLLSVAYKN3Homo sapiens, Bos taurus, Mus musculus
S53Homo sapiens, Bos taurus, Mus musculus
T217SYKDSTLIMQL3Homo sapiens, Bos taurus, Mus musculus
T228LRDNLTLWTAD3Homo sapiens, Bos taurus, Mus musculus
T90REKVETELRGV2Bos taurus, Mus musculus
T90REKVETELQGV1Homo sapiens
V178ALNFSVFHYEI3Homo sapiens, Bos taurus, Mus musculus
V46RNLLSVAYKNV3Homo sapiens, Bos taurus, Mus musculus
W230DNLTLWTADNA2Homo sapiens, Bos taurus
W230DNLTLWTADSA1Mus musculus
Y130GDYYRYLAEVA3Homo sapiens, Bos taurus, Mus musculus
Y181FSVFHYEIANS3Homo sapiens, Bos taurus, Mus musculus
Y213LSEDSYKDSTL3Homo sapiens, Bos taurus, Mus musculus
Y84PEVREYREKVE1Homo sapiens
Y84PEVQEYREKVE1Bos taurus
Y84PEVKEYREKVE1Mus musculus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas